Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy

NCT02948998 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

260

Enrollment

OTHER

Sponsor class

Conditions

Hypertrophic Cardiomyopathy
Fibrosis

Interventions

DRUG: Spironolactone

Sponsor

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Collaborators

[object Object]
[object Object]
[object Object]